JDPA Exam - Spring 2024

The SDPA offers a free Category 1 CME credit exam in each issue of the JDPA.  Successful completion of the self-assessment exam at 70% above will afford each learner 1.0 Category I CME credit.  **Please note that the accreditation expiration date for this activity is May 8, 2025.  You will not be able to access the activity in your enrolled courses after this date.

This exam is for the JDPA Spring 2024 issue. Questions 1-4 refer to the article beginning on page 16 entitled Dermatologic drug safety in lactation. This is a free CME service for SDPA members.

In 2014, the US FDA removed the Pregnancy Category Drug lettering system and enacted the “Pregnancy and Lactation Label Ruling.” This ruling required drug products to contain contact information for drug-specific exposure pregnancy registries, narrative-style sections summarizing the known effect of pregnancy, lactation counseling data, and data describing risks for females and males of reproductive potential. This new ruling has added more dialogue and discussion to the patient-provider decision-making process and requires clinicians to provide more individualized counseling based on the current medical literature. This article summarizes the recent evidence for the safety of the most common dermatological therapies for pregnant and lactating women.

Learning Objectives
After completion of this CME activity, participants should be able to:

• Discuss the changes from the US FDA’s lactation letter categories to Pregnancy Label Ruling with patients and colleagues.
• Compare the risks and benefits of dermatological treatment for currently lactating people, given the safety information available.
• Integrate important drug safety counseling points into practice for patients who can breastfeed.
• Describe evidence-based therapies for treating common dermatological conditions in lactation.